Phase 3 Trial for Mydriasis Medication
COMPLETED STUDY
MIRA – Phase 3 Trial for Mydriasis Medication
Disease/Condition
Pupil Dilation Reversal
Status
Completed
Description
Pharmacologically induced mydriasis, a key aspect of ophthalmologic exams and procedures, can lead to photophobia, discomfort and impairment of vision. Depending on the individual and the color of their eyes, the effects of dilation can last anywhere from 6 to over 24 hours. Currently, there are no available options to safely reverse mydriasis. The MIRA-2 study assessed the efficacy of 0.75% phentolamine ophthalmic solution (POS) to reverse pharmacologically induced mydriasis.
Study Dates
Completed February 2022
Take Part
If you’re interested in taking part in one of our studies, please fill out the contact form and one of our team members will get back to you promptly.